JPRN-UMIN000032854招募中未知
Immune checkpoint inhibitors and drug-induced colitis - Immune checkpoint inhibitors and drug-induced colitis
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who can not obtain consent 2. Patient undergoing antithrombotic therapy 3. When polyps that were judged to be resected for adaptation at the time of the initial colonoscopy are discovered 4. Patients with brachytherapy embedded for prostate cancer treatment
研究者
相似试验
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
进行中（未招募）
1 期
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
招募中
4 期
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
招募中
不适用
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
已完成
不适用
Incidence of immune checkpoint inhibitor-related myositisJPRN-UMIN000044960Yokohama City University Graduate School of Medicine12,866